الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 89 |  |  |
| | | from | 89 | | |
Abstract
Metastatic breast cancer is a treatable disease, however it remains incurable, so many efforts are continuously exerted trying to improve the survival of those patients. Genomic profiling is one of the challenging methods evolved to guide the treatment of MBC patients, however there is no clear indication to make the use of genomic profiling a routine practice in MBC settings.
Many studies were done providing no clear picture about the medical benefit of precision medicine for MBC. Also, no guidelines can help the clinicians to use the patients’ genomic data when planning treatment strategy. Gene profiling is recommended for MBC cases that are resistant to the standard therapy or for which no standard therapy is available and for those enrolled in a clinical trial.
This study included 48 patients who received genomic or non-genomic based chemotherapy in Alexandria and Cairo clinical oncology centers during the period from January 2013 to December 2017. They were randomized into two groups: control group and genomic group.
In the current study, invasive ductal carcinoma, grade II, luminal-A sub-type (ER, PR +ve, HER-2 -ve) were the most frequent histopathological findings in both groups. Triple negative sub-type was the second most frequent hormonal status in both groups.
In our study, the most common mutation identified among patients with genotyping results was PIK3CA, while TP53 was the second most common mutation.
In the current study, genomic profiling failed to improve the response rate, median progression free survival, however it improves the overall survival.